9 citations
,
December 2018 in “Cutaneous and Ocular Toxicology” Combined BRAF and MEK treatment increases rash risk but reduces other skin issues compared to BRAF alone.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
June 2024 in “Neuromuscular Disorders” Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
3 citations
,
July 2024 in “Archives of Dermatological Research” Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
2 citations
,
July 2023 in “JAAD Case Reports” A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.
January 2025 in “Biomedical Reports” Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.
1 citations
,
September 2025 in “JAAD reviews.” Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
26 citations
,
March 2014 in “Rheumatology” Some drugs used to treat inflammation may cause hair loss.